Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGM-1019 in NASH
NCT03676231Phase 2Terminated
- Sponsor
- Second Genome
- Start
- Jan 2019
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SGM-1019 in Nonalcoholic steatohepatitis (NASH) (3 arms), sponsored by Second Genome. Primary endpoint: Treatment-emergent Adverse Events at 12 weeks. Started Jan 2019; status: terminated.
02
Drugs
SGM-1019
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT03676231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03676231.